Signals, Powered By EquityPandit
Dr Reddy’s Laboratories Ltd, which is India’s second-largest drugmaker has posted 76% decline in its Q1 on account of fierce competition in its largest market, the United States.
For the April-June quarter, the net profit fell to Rs 154 crore from Rs 647 crore of previous year.
The total income for the quarter under review has declined 14% at Rs 3,234.5 crore as against Rs 3,757.8 crore of previous year.
